PDL Biopharma Second Quarter 2011 Net Income was $70.0 Million
Biotech Financial Reports 2011, August 1, 18, 8
-
- $5.99
-
- $5.99
Publisher Description
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), Incline Village, Nev. reported financial results for the second quarter ended June 30, 2011. Total revenues for the second quarter of 2011 were $122.1 million, compared to $120.3 million for the same period of 2010, a one percent year-over-year increase. Total revenues for the six months ended June 30, 2011, were $205.5 million, compared to $182.4 million for the same period of 2010. Included in results for the six months ended June 30, 2011, and not included in the same period in 2010, is a $10.0 million settlement payment from UCB Pharma S.A. resolving all legal disputes between the two companies. Excluding this one-time payment, revenue increased seven percent year over year for the six month period ended June 30, 2011.